IV-Edited MSCs for Osteoporosis: Can They Get Past the Lungs?. Can edited MSCs reach bone after an IV infusion? Understand lung trapping, bone-homing research, and the limits of a small osteoporosis study.
Most MSCs delivered intravenously are initially retained in the lungs. In a small 2026 osteoporosis study, researchers changed the cells' surface sugars to improve bone-marrow targeting, not to remove the lung barrier. Ten women received a single infusion and researchers reported encouraging bone and fracture observations. Because the study was uncontrolled and did not track cells into human bone, it cannot prove that the edited cells caused the improvements or establish this as standard osteoporosis care.
This article is for general informational and educational purposes only. It is not a substitute for personalized medical advice.
Imagine sending cells through a narrow hallway to reach the skeleton. Most stop at the first doorway: the lungs. So how could a study report improved bone measures after an IV infusion? That is the puzzle in Charles Lee, M.D.'s discussion of IV-edited MSCs for osteoporosis. His central point is worth separating into two questions: how many cells get past the lungs, and what happens to those that do?
At a glance:
The numbers explain the concern. As Lee describes it, laboratory-expanded MSCs are often about 15-25 micrometers across, while pulmonary capillary segments can be around 5-10 micrometers. Cells are deformable, but size and stickiness both matter. Experimental work describes the resulting pulmonary first-pass effect: many infused cells collect in lung vessels within minutes. Lee cites estimates of 50-90% initial lung retention; that range should not be treated as a measured percentage for the women in the osteoporosis study.
But the lung is not a sealed wall. Its vessels vary in width and can stretch; a minority of cells may pass. Lung signal can decline over the following day or two, although a later signal elsewhere may represent cell fragments inside immune cells rather than living cells that traveled there. Cells retained in the lungs may also release signaling substances or be cleared by immune cells. These possibilities do not prove that an IV infusion rebuilds human bone.
Researchers have explored smaller cells, different culture methods, split infusions, adhesion-blocking approaches, and alternative delivery routes to improve distribution. These are research ideas, not proven ways to improve osteoporosis outcomes. The original pulmonary first-pass study describes the delivery problem; it does not settle what happened in this particular trial.
The cells were not made smaller. Researchers collected bone marrow-derived MSCs from each participant and changed sugars on their surface before infusion. This process, called exofucosylation or glycocalyx editing, creates a surface feature called HCELL on the CD44 molecule. In earlier research, HCELL helped MSCs interact with E-selectin on bone-marrow blood vessels.
Think of it as adding a destination label to cells that make it past the lung filter. The proposed sequence is:
1. Pass: A fraction of infused cells reaches the broader circulation. 2. Slow: HCELL helps those cells tether and roll along marrow vessels. 3. Stop: Adhesion signals help them attach more firmly, with VLA-4 and VCAM-1 involved. 4. Enter: Some may move into marrow tissue, as seen in preclinical work.
This is a bone-homing strategy, not evidence that most cells bypassed the lungs. The surface change is temporary, and researchers did not directly track edited cells into the participants' bones. Lee also discusses other experimental targeting strategies, such as CXCR4 modification and bone-binding carriers. They use different methods and cannot be assumed to share this study's outcomes or safety profile.
What the study did and did not show:
In the 2026 Cell study by Moraleda and colleagues, ten women with advanced osteoporosis each received a single IV infusion of their own glycocalyx-edited bone marrow MSCs. The protocol evaluated them for two years, followed by more than three additional years of fracture and safety monitoring per participant. The registered study is NCT02566655.
Researchers reported:
Lee's article cites a striking change in annual fragility fractures, from 8 to 0.5, but a before-and-after comparison in ten people is not a treatment success rate. The study had no randomized control group, many participants also received standard osteoporosis medicines, and the cells were not tracked in human bone. These encouraging observations cannot tell us how much, if any, of the improvement was caused by the edited cells. It also cannot rule out uncommon harms.
One interesting detail: the participants used their own bone marrow cells despite having advanced osteoporosis. The observations challenge the assumption that cells from older or affected donors are automatically unusable, but do not prove that all such cells will work.
Osteoporosis affects the whole skeleton, which makes the idea of a marrow-targeting bloodstream route interesting. Yet a plausible mechanism is not proof of benefit. For related background, see how chronic inflammation affects bone health.
The immediate priority is proven fracture-risk care, not replacing prescribed treatment with an experimental infusion. A clinician can review bone density, prior fractures, fall risk, possible secondary causes, and suitable established medicines.
If a research study interests you, ask:
Bottom line: Lee's size objection is valid, but incomplete. The lungs filter many cells; a temporary bone-homing edit may improve where the small fraction that escapes ends up. The ten-person study makes that idea worth testing, not offering as a proven osteoporosis treatment.